Table 2.

Current lung organoid/tumoroid models.

Primary Tumor Histology, (Mutations) *	Technology Name	Culture Time	Applications	Ref.
NS	Patient-derived tumor spheroid (PDS)	120 days	Mechanistic studies Resistant models Drug screening	[38]
ADK, SCC, LCC	Lung cancer organoids	>1 year	Drug screening	[39]
ADK, SCC, LCC	Patient-derived lung cancer organoids	>6 months	Patient-specific drugs screening Living biobank as support to xenograft model	[24]
ADK, SCC	NSCLC organoids	3 months	Drug screening	[37]
ADK, SCC NSCLC (EGFR, KRAS)	Patient-derived organoids models (PDOs)	NS	Genomic analyses Production of treatment response	[40]
NSCLC (EGFR, KRAS)	Patient lung-derived tumoroids (PLDTs)	NS	Drug screening	[41]
ADK, SCC, LCC, NSCLC	Lung cancer organoids	NS	Personalized medicine	[36]
NS	Patient-derived organoids (PDOs)	2–3 months	Drug screening Comparative analysis	[42]
ADK	Lung ADK (LADC)-derived organoid model	>50–200 days	Transcriptome analysis Biomarkers discovery Drug screening Living biobank	[35]
ADK and SCC	Lung cancer organoids	6 days	Drug screening	[43]
ADK and SCC primary or metastatic NSCLC	Patient-derived tumoroids (PDTs)	>13 months	Generation of cell lines	[44]
ADK	Patient-derived tumoroids (PDTs)	4 days	Mimic the tumor vascular network PDTs ready to use in microfluidic device for drug screening	[45]

* ADK: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large cell carcinoma, NS: non specified.